Penicillin or Ceftriaxone for Neurosyphilis in People With HIV: A Retrospective, Propensity Score–Matched Multicenter Study in Mexico
Authors:
- Rodrigo Ville BenavidesRBRodrigo Ville Benavides
- Héctor Rivera-VillegasHRHéctor Rivera-Villegas
- Obed Ocampo-ValdezOOObed Ocampo-Valdez
- Rafael Franco-CendejasRFRafael Franco-Cendejas
- Jaime Federico Andrade-VillanuevaJAJaime Federico Andrade-Villanueva
- Luz Alicia González-HernándezLGLuz Alicia González-Hernández
- Pedro Martínez-AyalaPMPedro Martínez-Ayala
- Andrea Cárdenas-OrtegaAndrea Cárdenas-Ortega
- Paulina Carreño-PérezPCPaulina Carreño-Pérez
- Juan Carlos Rodríguez-AldamaJRJuan Carlos Rodríguez-Aldama
- Edgar Pérez-BarragánEPEdgar Pérez-Barragán
Open Access
- 1 July 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7) , ofag387
Abstract
Background: Neurosyphilis, ocular syphilis, and otosyphilis occur more frequently among people with HIV-1 and are associated with higher morbidity and treatment failure. Intravenous penicillin G remains the standard therapy but requires hospitalization or prolonged intravenous access, creating barriers that are amplified in resource-limited settings facing recurrent penicillin shortages. Ceftriaxone is a potential alternative; however, comparative data in people with HIV are limited. Methods: We conducted a multicenter retrospective cohort study of adults with HIV at 5 public hospitals and 2 outpatient HIV clinics in Mexico (2015–2024). Participants had confirmed neurosyphilis, ocular syphilis, or otosyphilis. Participants received intravenous penicillin G (18–24 million IU/day) or ceftriaxone (1–2 g/day) for 10–14 days. The primary outcome was early serological response (ESR), defined as a ≥4-fold nontreponemal titer decline or seroreversion at 6 months. We performed 1:1 propensity score matching (39 pairs, n = 78), followed by logistic regression in the matched cohort. Results: Of 143 participants, 104 (73%) received intravenous penicillin G and 39 (27%) ceftriaxone. In the matched cohort, ESR occurred in 74.4% of penicillin-treated participants and 71.8% of ceftriaxone-treated participants (odds ratio 0.88, 95% confidence interval .32–2.40; P = .80). The results were consistent across all prespecified sensitivity analyses. Conclusions: In this multicenter cohort of people with HIV diagnosed with neurosyphilis, ocular syphilis, or otosyphilis, ceftriaxone showed comparable ESR to intravenous penicillin G. These findings support ceftriaxone as a reasonable alternative when standard therapy is limited by penicillin shortages, limited inpatient capacity, or financial constraints.Keywords
This publication has 33 references indexed in Scilit:
- Research priorities for advanced HIV disease in Latin America and the Caribbean region: a modified Delphi studyJournal of the International AIDS Society, 2026
- Expanding Horizons in Syphilis Treatment: Challenges, Advances, and Opportunities for Alternative AntibioticsCurrent HIV/AIDS Reports, 2025
- Outpatient Oral Doxycycline Therapy for Ocular SyphilisJAMA Network Open, 2024
- Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2024
- Neurological manifestations of syphilis-HIV coinfection in South AfricaJournal of the Neurological Sciences, 2023
- Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre studyThe Lancet Infectious Diseases, 2021
- Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical studyEBioMedicine, 2021
- La ceftriaxone est non-inférieure à la pénicilline G dans le traitement de la neurosyphilisMedecine Et Maladies Infectieuses, 2020
- Genomic epidemiology of syphilis reveals independent emergence of macrolide resistance across multiple circulating lineagesNature Communications, 2019
- Intravenous Ceftriaxone for Syphilitic UveitisOcular Immunology and Inflammation, 2017